The downgrade from Outperform to Neutral by Wedbush analyst Andreas Argyrides indicates a less optimistic outlook for Unity Biotechnology's stock performance. The lowered price target from $3 to $2 also suggests a reduced potential upside for the stock, which may negatively impact its short-term price.